Alternative R&D models


Indus­try often argues that intel­lec­tual prop­erty monop­o­lies and reliance on high prices are nec­es­sary to incen­tivize the research and devel­op­ment of novel health prod­ucts. Some gov­ern­ments and other stake­hold­ers often echo these claims. These argu­ments are typ­i­cally raised to jus­tify research and devel­op­ment mod­els where the result­ing health prod­ucts, includ­ing tech­nolo­gies for the diag­nos­tics, pre­ven­tion and treat­ment of HIV, are unavail­able or inac­ces­si­ble to many of those who need them. Con­trary to these claims, how­ever, alter­na­tive research and devel­op­ment incen­tives mod­els have been explored and imple­mented to encour­age the devel­op­ment of health prod­ucts.

Alter­na­tive R&D mod­els is a broad term used in the Lan­guage Com­pendium to refer to all alter­na­tive mod­els for encour­ag­ing research and devel­op­ment that depart from a reliance on exclu­sive intel­lec­tual prop­erty rights and high prices. These alter­na­tive R&D mod­els include mod­els based on the prin­ci­ple of delink­ing fund­ing of R&D from prod­uct prices.


2022 HRC Res­o­lu­tion on access to medicines, vaccines and other health products

2021 HRC Res­o­lu­tion on ensuring equitable, affordable, timely and universal access for all countries to vaccines in response to COVID-19

2019 HRC Resolution on access to medicines and vaccines